Tillkännagivande • Jun 20
Lenzing Ag Highlights Scalable Bio-Based Nonwovens Solutions and Receives Index 26 Award for Lenzing Dualwipe Lenzing AG further strengthened the positioning of its nonwovens business during a series of major international industry fairs in the first half of 2026. From CIDPEX in China to Techtextil in Frankfurt and INDEX in Geneva, Lenzing demonstrated how its nonwovens fiber portfolio and LENZING Nonwoven Technology (LNT) enable scalable, bio-based alternatives to fossil-based nonwoven materials. At Techtextil 2026 in Frankfurt and INDEX 2026 in Geneva, LENZING Nonwoven Technology was presented through interactive touch and feel stations that attracted strong industry interest. These hands-on demonstrations allowed visitors to experience the performance, versatility, and material benefits of Lenzing’s cellulosic nonwoven solutions in an application-oriented context. A central highlight was the recognition of LENZING DualWipe with the prestigious INDEX Award in the Nonwovens Roll Goods category at the INDEX fair in Geneva. This innovative wipe, enabled by the LENZING Nonwoven Technology, integrates two functional surfaces within a single wipe: an abrasive side for effective removal of dirt and residues, and a soft, highly absorbent side for wiping and finishing. DualWipe contains no synthetic fibers, binders, or finishing chemicals, eliminating the risk of microplastic shedding typically associated with conventional synthetic wipes. Lenzing’s nonwovens solutions are aligned with the EU Bioeconomy Strategy, which emphasizes the use of bio-based materials to reduce dependence on fossil resources and strengthening sustainable industrial value chains. Lenzing translates these strategic ambitions into industrial-scale solutions that are already available for applications in hygiene, wipes and technical nonwovens. Across all fairs, Lenzing demonstrated how its fibers and technologies add value to diverse end applications, with a particular focus on absorbent hygiene products and advanced nonwoven solutions. Tillkännagivande • Jun 01
Lenzing AG Announces Appoints Georg Kasperkovitz as Chief Executive Officer, Effective June 1, 2026 Lenzing AG had appointed Georg Kasperkovitz, Member of the Management Board and Chief Operations Officer, as Chief Executive Officer (CEO) of Lenzing AG with effect from June 1, 2026. Kasperkovitz will assume this role in addition to his current function as Chief Operations Officer (COO). Kasperkovitz has been a member of the Management Board of Lenzing AG as Chief Operations Officer since June 2025. In this role, he has most recently led the Fiber Division (sales, production, and supply chain) as well as the further development and execution of the performance program. He has achieved significant progress in operational excellence and the profitability of the fiber production sites. As CEO, in addition to overseeing the company-wide fiber production sites, he will also assume global responsibility for fiber sales, supply chain, and human resources. Kasperkovitz's mandate as CEO runs for three years until May 31, 2029. Kasperkovitz holds a PhD in Mechanical Engineering (Vienna University of Technology) and an MBA from Harvard Business School. He has more than 15 years of international management experience across Europe, North America, Asia, and China-Lenzing's key production regions and markets. Prior to joining Lenzing, he served as Business Unit CEO at the international packaging and paper company Mondi plc (2016–2019) and as CEO of Rail Cargo Austria AG (2012–2016). He previously worked as a partner at the global consulting firm McKinsey & Company. Reported Earnings • May 11
First quarter 2026 earnings released: EPS: €0.01 (vs €0.12 in 1Q 2025) First quarter 2026 results: EPS: €0.01 (down from €0.12 in 1Q 2025). Revenue: €615.7m (down 11% from 1Q 2025). Net income: €300.0k (down 94% from 1Q 2025). Profit margin: 0% (down from 0.7% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 20
Full year 2025 earnings released: €5.45 loss per share (vs €4.06 loss in FY 2024) Full year 2025 results: €5.45 loss per share (further deteriorated from €4.06 loss in FY 2024). Revenue: €2.60b (down 2.3% from FY 2024). Net loss: €210.3m (loss widened 34% from FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 17
No longer forecast to breakeven The 5 analysts covering Lenzing no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €49.9m in 2027. New consensus forecast suggests the company will make a loss of €60.8m in 2027. Tillkännagivande • Feb 03
Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB. Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB on February 2, 2026. The transaction is executed through the issuance of new shares. After the acquisition Lenzing Aktiengesellschaft will own majority stake in TreeToTextile AB.
Lenzing Aktiengesellschaft (WBAG:LNZ) completed the acquisition of additional unknown minority stake in TreeToTextile AB on February 2, 2026. Tillkännagivande • Dec 09
Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026 Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026. Reported Earnings • Aug 08
Second quarter 2025 earnings released: €1.02 loss per share (vs €1.01 loss in 2Q 2024) Second quarter 2025 results: €1.02 loss per share (further deteriorated from €1.01 loss in 2Q 2024). Revenue: €650.9m (flat on 2Q 2024). Net loss: €39.4m (loss widened 1.0% from 2Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year and the company’s share price has also fallen by 31% per year. Reported Earnings • May 13
First quarter 2025 earnings released: EPS: €0.12 (vs €0.83 loss in 1Q 2024) First quarter 2025 results: EPS: €0.12 (up from €0.83 loss in 1Q 2024). Revenue: €690.2m (up 4.8% from 1Q 2024). Net income: €4.70m (up €36.7m from 1Q 2024). Profit margin: 0.7% (up from net loss in 1Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 18
Lenzing Announces Supervisory Board Changes Lenzing at its annual general meeting, appointed Patrick Lackenbucher and Leonardo Grimaldi to the supervisory board until 2029. They replace Cord Prinzhorn, whose term expired, and Marcelo Feriozzi Bacci, who resigned from the board in December 2024, according to a company statement on Thursday. Tillkännagivande • Apr 03
The Lenzing Group Announces Board Member and Chief Transformation Officer Walter Bickel Will Leave Company At the End of March 2025 The Lenzing Group announced personnel changes in the company’s Managing Board. The Supervisory Board of Lenzing AG and Dr. Walter Bickel, Chief Transformation Officer of Lenzing AG, have mutually agreed to end the temporary mandate of Mr. Bickel and that Mr. Bickel will step down from his operational activities at the end of March 2025. Mr. Bickel was appointed to the Managing Board of Lenzing AG as of April 15, 2024 to strengthen the Lenzing Managing Board and to be responsible for the further development and implementation of the performance program. Under his leadership, a significant overachievement of the planned contributions from the performance program could be realized. The basis for future significant improvement steps is established, and the program has been structured in a way that it can now be continued by Lenzing AG seamlessly. Reported Earnings • Mar 16
Full year 2024 earnings released: €4.06 loss per share (vs €20.02 loss in FY 2023) Full year 2024 results: €4.06 loss per share (improved from €20.02 loss in FY 2023). Revenue: €2.66b (up 5.7% from FY 2023). Net loss: €156.6m (loss narrowed 76% from FY 2023). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 3.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Tillkännagivande • Mar 12
Cord Prinzhorn Not Stand for Re-Election as Member of Lenzing AG's Supervisory Board The Chairman of the Supervisory Board of Lenzing AG, Cord Prinzhorn, has informed the Nomination Committee of the Supervisory Board that he will not extend his term as a member of the company’s Supervisory Board after the Annual General Meeting on April 17, 2025 and will not stand for re-election at the upcoming Annual General Meeting. Cord Prinzhorn intends to devote more time to his existing and new activities at the B&C Group. Mr. Prinzhorn will thus leave the Supervisory Board of Lenzing AG at the end of the Annual General Meeting. Tillkännagivande • Jan 27
Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025 Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025. Reported Earnings • Nov 09
Third quarter 2024 earnings released: €1.66 loss per share (vs €0.97 loss in 3Q 2023) Third quarter 2024 results: €1.66 loss per share (further deteriorated from €0.97 loss in 3Q 2023). Revenue: €647.5m (up 5.2% from 3Q 2023). Net loss: €64.1m (loss widened 45% from 3Q 2023). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 06
Lenzing Nonwovens Expands its LENZING Lyocell Dry Fiber Portfolio to Offer Cellulosic Solutions for a Wider Range of Applications Lenzing Nonwovens announced the expansion of its LENZING Lyocell Dry fiber portfolio with two new cellulosic fibers – a fine dry fiber that delivers strength and softness and a coarse dry fiber which provides enhanced liquid and air flow. These two innovative products enable customers to confidently broaden their use of LENZING's wood-based and biodegradable fibers into a wider range of applications while maintaining exceptional performance. All LENZING Lyocell Dry fibers within the family (standard, fine, and coarse) have hydrophobic properties which ensure efficient liquid management suitable for extensive nonwoven applications. The new LENZING Lyocell Dry fine fiber can produce nonwoven fabrics with higher density compared to LENZING Lyocell Dry standard fiber. With up to 30% more cellulosic fibers in the same space, customers can create strong and soft nonwoven products. These fibers are suitable for use in hygiene applications such as diapers or sanitary pads. The new LENZING Lyocell Dry coarse fiber creates fabrics that are more open due to its extended fiber diameter, and thus increasing the pore sizes between the fibers in the fabric. This allows for more air or liquid to flow through the material. It is particularly suitable for the acquisition and distribution layer in hygiene products and is also being explored for industrial filtration applications. Lenzing will showcase its innovative LENZING Lyocell Dry fiber family at tabletop 202 during the Hygienix Conference, November 18-21, 2024. Facts and figures: LENZING Lyocell Dry fine has a linear density of 1.3dtex; LENZING Lyocell Dry standard has a linear density of 1.7dtex; Fabrics produced using LENZING Lyocell Dry fine and standard have the same basis weight (eg. 50gsm) but the "fine" material has a higher density with up to 30% more fibers in the same space. LENZING Lyocell Dry coarse has a linear density of 6.3dtex. Tillkännagivande • Aug 22
Lenzing Aktiengesellschaft Announces CEO Changes Lenzing Aktiengesellschaft announced Stephan Sielaff to leave the company as of August 31, 2024. Rohit Aggarwal will take over the position of CEO as of 1 September 2024. Outgoing Chief Executive Officer Stephan Sielaff will leave the company end of August 2024, by mutual agreement with the Supervisory Board. Reported Earnings • Aug 08
Second quarter 2024 earnings released: €1.01 loss per share (vs €0.89 loss in 2Q 2023) Second quarter 2024 results: €1.01 loss per share (further deteriorated from €0.89 loss in 2Q 2023). Revenue: €652.3m (up 4.0% from 2Q 2023). Net loss: €39.0m (loss widened 65% from 2Q 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Reported Earnings • May 09
First quarter 2024 earnings released: €0.83 loss per share (vs €3.03 loss in 1Q 2023) First quarter 2024 results: €0.83 loss per share (improved from €3.03 loss in 1Q 2023). Revenue: €658.4m (up 5.7% from 1Q 2023). Net loss: €32.0m (loss narrowed 60% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. New Risk • May 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.0% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding). Reported Earnings • Mar 16
Full year 2023 earnings released: €20.02 loss per share (vs €2.75 loss in FY 2022) Full year 2023 results: €20.02 loss per share (further deteriorated from €2.75 loss in FY 2022). Revenue: €2.52b (down 1.7% from FY 2022). Net loss: €649.4m (loss widened €576.4m from FY 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Tillkännagivande • Feb 01
Lenzing Group Teams Up with Recyc Leather and Ganni to Unveil New Footwear Materials Lenzing Group has partnered with leather alternative expert Recyc Leather to introduce Pelinova, an innovative material that fuses TENCEL™? Lyocell fibers and recycled leather fibers for high-end fashion applications. Joining forces with Danish advanced contemporary brand GANNI, this dynamic trio is set to bring this next-generation material to the market as an alternative to genuine leather materials, starting with GANNI's Slouchy Boots launching early this year. Pelinova: a hybrid alternative combining TENCEL™? L Tokyocell fibers and recycled leather fibers. Recyc Leather's next-generation material, Pelinova®?, is created through a unique, transparent process which involves collecting pre-consumer recycled leather and then hydro-jetting the leather fibers into the TENCEL™? Lanocell fibers, a standout material within the TENCEL™? brand portfolio that is produced from a resource-saving, closed-loop production process. TENCEL™? Liocell fibers are also unfavorable to odor-causing bacteria. The combined efforts between Lenzing and Recyc Leather result in a material which is supple, flexible, and durable, with a low environmental impact utilizing 70% less water than traditional methods and reducing CO2 emissions. Riding on this exciting breakthrough in footwear, Recyc Leather is also exploring the possibility of expanding the fabric application to other leather goods spanning home textiles, furniture, automobile interiors and the luxury segment. Elevating the GANNI partnership: GANNI is a B Corp. certified company, on a journey to become the most responsible version of itself. They believe it's a moral obligation to do better every day. GANNI is committed to minimizing social and environmental impact within its business operation with a goal to reach 50% absolute carbon reduction by 2027, with materials and innovation among its key pillars in reaching this target. In addition to footwear, GANNI sees the application of Recyc Leather's Pelinova®? with TENCEL™? Lycell fibers in the accessories category. GANNI, Recyc Leather, and Lenzing have future developments in the pipeline to get even closer to being able to scale the use of the material. During Premiere Vision Paris (PV Paris, February 6-8), Lenzing will be joined by Recyc Leather and GANNI at a panel discussion to share their collaborative experiences as a prime example of how companies can unite to create high-end fashion using responsibly produced recycled materials. For more interactive participation, visit the TENCEL™? brands at Booth 6D67 and Recyc Leather at Booth 6HUB11. Savings consider solvent recovery. The responsible production of TENCEL™? LTokcell and Modal fibers uses at least 50% less water and emits at least 50% less water. The responsible production of TENEL™? Lyocell and Modal fibers uses At least 50% less water and emissions at least 50% less water, and emits at least 50% more water. New Risk • Nov 06
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding). Reported Earnings • Nov 04
Third quarter 2023 earnings released: €0.97 loss per share (vs €0.20 loss in 3Q 2022) Third quarter 2023 results: €0.97 loss per share (further deteriorated from €0.20 loss in 3Q 2022). Revenue: €615.5m (down 9.0% from 3Q 2022). Net loss: €44.3m (loss widened €39.0m from 3Q 2022). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 02
Second quarter 2023 earnings released: €0.89 loss per share (vs €1.49 profit in 2Q 2022) Second quarter 2023 results: €0.89 loss per share (down from €1.49 profit in 2Q 2022). Revenue: €627.1m (down 7.6% from 2Q 2022). Net loss: €23.7m (down 160% from profit in 2Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. New Risk • Jul 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 45% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 171% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding). Tillkännagivande • Jul 07
Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million. Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 12,068,180
Price\Range: €33.1
Transaction Features: Rights Offering New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 171% Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Reported Earnings • May 03
First quarter 2023 earnings released: €3.03 loss per share (vs €0.87 profit in 1Q 2022) First quarter 2023 results: €3.03 loss per share (down from €0.87 profit in 1Q 2022). Revenue: €623.1m (up 1.3% from 1Q 2022). Net loss: €80.5m (down 450% from profit in 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Mar 11
Full year 2022 earnings released: €2.75 loss per share (vs €4.16 profit in FY 2021) Full year 2022 results: €2.75 loss per share (down from €4.16 profit in FY 2021). Revenue: €2.57b (up 17% from FY 2021). Net loss: €73.1m (down 166% from profit in FY 2021). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 19% share price gain to €65.30, the stock trades at a forward P/E ratio of 548x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 17% over the past three years. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €54.45, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 33% over the past three years. Reported Earnings • Nov 05
Third quarter 2022 earnings released: €0.20 loss per share (vs €0.71 profit in 3Q 2021) Third quarter 2022 results: €0.20 loss per share (down from €0.71 profit in 3Q 2021). Revenue: €676.5m (up 22% from 3Q 2021). Net loss: €5.30m (down 128% from profit in 3Q 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 9.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 17% share price gain to €55.65, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorated over the past week After last week's 17% share price decline to €52.00, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 39% over the past three years. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment deteriorated over the past week After last week's 26% share price decline to €58.05, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 31% over the past three years. Reported Earnings • Aug 04
Second quarter 2022 earnings released: EPS: €1.49 (vs €2.00 in 2Q 2021) Second quarter 2022 results: EPS: €1.49 (down from €2.00 in 2Q 2021). Revenue: €678.6m (up 25% from 2Q 2021). Net income: €39.7m (down 25% from 2Q 2021). Profit margin: 5.9% (down from 9.8% in 2Q 2021). Over the next year, revenue is forecast to grow 10% compared to a 21% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • May 08
First quarter 2022 earnings released: EPS: €0.87 (vs €1.06 in 1Q 2021) First quarter 2022 results: EPS: €0.87. Revenue: €615.0m (up 26% from 1Q 2021). Net income: €38.0m (up 55% from 1Q 2021). Profit margin: 6.2% (up from 5.0% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14% compared to a 17% decline forecast for the industry in the United Kingdom. Upcoming Dividend • Apr 21
Upcoming dividend of €4.35 per share Eligible shareholders must have bought the stock before 28 April 2022. Payment date: 03 May 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 4.8%. Within top quartile of British dividend payers (4.6%). Higher than average of industry peers (2.6%). Reported Earnings • Mar 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: €4.16 (up from €0.24 in FY 2020). Revenue: €2.19b (up 30% from FY 2020). Net income: €110.3m (up €104.1m from FY 2020). Profit margin: 5.0% (up from 0.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 18% compared to a 12% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Reported Earnings • Nov 06
Third quarter 2021 earnings released: EPS €0.71 (vs €0.16 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €555.2m (up 44% from 3Q 2020). Net income: €18.8m (up €23.1m from 3Q 2020). Profit margin: 3.4% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Executive Departure • Oct 07
Chairman of Management Board & CEO Stefan Doboczky has left the company During their tenure, earnings grew by 24% annually compared to the industry average of 4.6%. On the 30th of September, Stefan Doboczky left the company after 6.3 years in the role. We don't have any record of a personal shareholding under Stefan's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.17 years. Under Stefan's leadership, the company delivered a total shareholder return of 90%. Reported Earnings • Aug 05
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €544.0m (up 52% from 2Q 2020). Net income: €60.4m (up €81.1m from 2Q 2020). Profit margin: 11% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Executive Departure • Apr 20
Independent Deputy Chairman of Supervisory Board Veit Sorger has left the company On the 14th of April, Veit Sorger's tenure as Independent Deputy Chairman of Supervisory Board ended after 10.1 years in the role. We don't have any record of a personal shareholding under Veit's name. A total of 2 executives have left over the last 12 months. Analyst Estimate Surprise Post Earnings • Mar 12
Revenue misses expectations Revenue missed analyst estimates by 1.6%. Over the next year, revenue is forecast to grow 15% compared to a 8.5% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Mar 12
Full year 2020 earnings released: EPS €0.24 (vs €4.63 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.75b (down 19% from FY 2019). Net income: €6.28m (down 95% from FY 2019). Profit margin: 0.4% (down from 5.7% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 01
New 90-day high: €121 The company is up 67% from its price of €72.30 on 01 December 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €182 per share. Is New 90 Day High Low • Feb 06
New 90-day high: €115 The company is up 84% from its price of €62.50 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €183 per share. Is New 90 Day High Low • Jan 20
New 90-day high: €102 The company is up 83% from its price of €55.65 on 22 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €176 per share. Is New 90 Day High Low • Dec 29
New 90-day high: €79.60 The company is up 70% from its price of €46.90 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €156 per share. Is New 90 Day High Low • Dec 10
New 90-day high: €75.35 The company is up 67% from its price of €45.10 on 10 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €126 per share. Is New 90 Day High Low • Nov 07
New 90-day high: €64.60 The company is up 60% from its price of €40.45 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €219 per share. Analyst Estimate Surprise Post Earnings • Nov 05
Revenue misses expectations Revenue missed analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 7.6% compared to a 14% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Nov 05
Third quarter 2020 earnings released: €0.16 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €413.4m (down 24% from 3Q 2019). Net loss: €4.30m (down 111% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 16
New 90-day high: €53.80 The company is up 27% from its price of €42.50 on 17 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €133 per share. Is New 90 Day High Low • Sep 29
New 90-day high: €47.10 The company is up 15% from its price of €41.00 on 01 July 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €94.98 per share. 
